Home Interviews CLS on a Q3 characterised by US-advancement

CLS on a Q3 characterised by US-advancement

CLS vd Dan Mogren i BioStocks studio i Lund

CLS on a Q3 characterised by US-advancement

23 November, 2022

Medtech Clinical Laserthermia Systems, CLS, can look back on a third quarter characterised by advancement on the US market. In September, the company received FDA clearance for the use of CLS system for laser ablation in neurosurgery, and the US commercialisation is now initiated. CEO Dan Mogren visited BioStock’s studio to talk about the past quarter.

See the interview with CLS CEO Dan Mogren below.

The content of BioStock’s news and analyses is independent but the work of BioStock is to a certain degree financed by life science companies. The above article concerns a company from which BioStock has received financing.

Prenumerera på BioStocks nyhetsbrev